Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant
Por um escritor misterioso
Descrição
New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer: Molecular Therapy - Oncolytics
ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650
PDF) Long-term complete remission with Ipilimumab in metastatic castrate- resistant prostate cancer: Case report of two patients
Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer - ecancer
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial - The Lancet Oncology
Biomedicines, Free Full-Text
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - Beyond the Abstract
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial - ScienceDirect
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies - McGregor - 2021 - Cancer - Wiley Online Library
de
por adulto (o preço varia de acordo com o tamanho do grupo)
